

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



G1 C, N

G2 H, X, OH, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 16:27:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 260 TO ITERATE

100.0% PROCESSED 260 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 4233 TO 6167

PROJECTED ANSWERS: 22 TO 418

L2 11 SEA SSS SAM L1

=> s 11 sss full

FULL SEARCH INITIATED 16:27:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5616 TO ITERATE

100.0% PROCESSED 5616 ITERATIONS

111 ANSWERS

SEARCH TIME: 00.00.02

L3 111 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

Habte

<05/15/2002

Jan. 17/2003

FULL ESTIMATED COST

140.28

140.49

FILE 'CAPLUS' ENTERED AT 16:28:02 ON 15 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 May 2002 VOL 136 ISS 20
FILE LAST UPDATED: 14 May 2002 (20020514/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13

L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:314905 CAPLUS
DOCUMENT NUMBER: 136:309847
TITLE: 2-, 3-, 4-, or 5-substituted-1-
(benzenesulfonyl)indoles and their use in therapy
INVENTOR(S): Caldirola, Patrizia; Johansson, Gary; Nilsson, Bjoern M.
PATENT ASSIGNEE(S): Biovitrum AB, Swed.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032863	A1	20020425	WO 2001-SE2319	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

Habte

<05/15/2002

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

SE 2000-3810 A 20001020

US 2000-243115P P 20001025

AB Approx. 130 title compds. and their HCl salts were prepd. by std. methods.


The said compds. have affinity for the 5-HT₆ receptor and are useful for the treatment and prophylaxis of disorders relating to the said receptor, such as obesity and CNS disorders.

IT 393508-48-0 412049-80-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of antiobesity benzenesulfonylindoles)


RN 393508-48-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 412049-80-0 CAPLUS

CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



IT 412049-09-3P 412049-39-9P 412049-41-3P

Habte

<05/15/2002

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(prepn. of antiobesity benzenesulfonylindoles)

RN 412049-09-3 CAPLUS

CN 1H-Indole, 5-(4-methyl-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA


INDEX

NAME)




RN 412049-39-9 CAPLUS

CN 1-Piperazinecarboxylic acid,
4-[2-iodo-1-(phenylsulfonyl)-1H-indol-4-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 412049-41-3 CAPLUS

CN 1-Piperazinecarboxylic acid,
4-[2-phenyl-1-(phenylsulfonyl)-1H-indol-4-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 393508-47-9P 412048-49-8P 412048-50-1P
 412048-51-2P 412048-52-3P 412048-53-4P
 412048-54-5P 412048-55-6P 412048-56-7P
 412048-57-8P 412048-58-9P 412048-59-0P
 412048-61-4P 412048-63-6P 412048-64-7P
 412048-65-8P 412048-66-9P 412048-67-0P
 412048-68-1P 412048-69-2P 412048-70-5P
 412048-71-6P 412048-72-7P 412048-73-8P
 412048-75-0P 412048-76-1P 412048-79-4P
 412048-80-7P 412048-81-8P 412048-84-1P
 412048-85-2P 412048-86-3P 412048-87-4P
 412048-89-6P 412048-90-9P 412048-91-0P
 412048-92-1P 412048-93-2P 412048-94-3P
 412048-95-4P 412048-96-5P 412048-97-6P
 412048-98-7P 412048-99-8P 412049-00-4P
 412049-01-5P 412049-02-6P 412049-03-7P
 412049-04-8P 412049-05-9P 412049-10-6P
 412049-11-7P 412049-12-8P 412049-13-9P
 412049-14-0P 412049-15-1P 412049-16-2P
 412049-17-3P 412049-18-4P 412049-19-5P
 412049-20-8P 412049-21-9P 412049-22-0P
 412049-23-1P 412049-24-2P 412049-25-3P
 412049-26-4P 412049-27-5P 412049-28-6P
 412049-29-7P 412049-30-0P 412049-31-1P
 412049-32-2P 412049-33-3P 412049-34-4P
 412049-35-5P 412049-36-6P 412049-37-7P
 412049-40-2P 412049-42-4P 412049-45-7P
 412049-49-1P 412049-50-4P 412049-51-5P
 412049-54-8P 412049-55-9P 412049-56-0P
 412049-57-1P 412049-59-3P 412049-60-6P
 412049-61-7P 412049-62-8P 412049-63-9P
 412049-64-0P 412049-65-1P 412049-66-2P
 412049-67-3P 412049-68-4P 412049-69-5P
 412049-70-8P 412049-71-9P 412049-72-0P
 412049-73-1P 412049-74-2P 412049-75-3P
 412049-76-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of antiobesity benzenesulfonylindoles)

RN 393508-47-9 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 412048-49-8 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, dihydrochloride (9CI)
(CA INDEX NAME)



● 2 HCl


RN 412048-50-1 CAPLUS

CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-51-2 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-52-3 CAPLUS
CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-53-4 CAPLUS


CN 1H-Indole, 1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-54-5 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[(4-propoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-55-6 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-56-7 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-57-8 CAPLUS


CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-58-9 CAPLUS


CN 1H-Indole, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-59-0 CAPLUS


CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-61-4 CAPLUS


CN 1H-Indole, 1-[(2-methoxy-5-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-63-6 CAPLUS


CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-64-7 CAPLUS

CN 1H-Indole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-65-8 CAPLUS
 CN 1H-Indole, 1-[(3-chloro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-66-9 CAPLUS
 CN 1H-Indole, 1-[[4-(4-chloro-3-cyanophenoxy)phenyl]sulfonyl]-4-(1-
 piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-67-0 CAPLUS


CN 1H-Indole, 1-[(5-bromo-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-68-1 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-69-2 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-7-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-70-5 CAPLUS
 CN 1H-Indole, 1-[[2-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-71-6 CAPLUS


CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-72-7 CAPLUS


CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-
piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-73-8 CAPLUS


CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-75-0 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[4-(trifluoromethyl)phenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-76-1 CAPLUS

CN 1H-Indole,


4-(3-methyl-1-piperazinyl)-1-[[4-(trifluoromethyl)phenyl]sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 412048-79-4 CAPLUS


CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)



RN 412048-80-7 CAPLUS

CN 1H-Indole, 4-(4-ethyl-1-piperazinyl)-1-[(2-methylphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)


RN 412048-81-8 CAPLUS

CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)

RN 412048-84-1 CAPLUS

CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(3-methyl-1-piperazinyl)- (9CI)


(CA INDEX NAME)



RN 412048-85-2 CAPLUS


CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 412048-86-3 CAPLUS


CN 1H-Indole, 4-[4-(1-methylethyl)-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 412048-87-4 CAPLUS

CN 1H-Indole, 4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 412048-89-6 CAPLUS


CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(phenylsulfonyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 412048-90-9 CAPLUS

CN 1H-Indole, 4-(4-ethyl-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 412048-91-0 CAPLUS

CN 1H-Indole, 1-[(4-nitrophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-92-1 CAPLUS

CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA

INDEX
NAME)


RN 412048-93-2 CAPLUS

CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)

RN 412048-94-3 CAPLUS


CN 1H-Indole, 1-[[(1E)-2-phenylethenyl]sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 412048-95-4 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)



RN 412048-96-5 CAPLUS


CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX
NAME)



RN 412048-97-6 CAPLUS

CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-


piperazinyl)- (9CI) (CA INDEX NAME)



RN 412048-98-7 CAPLUS


CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA

INDEX
NAME)




RN 412048-99-8 CAPLUS


CN 1H-Indole, 1-[(4-phenoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)




RN 412049-00-4 CAPLUS
 CN 1H-Indole, 1-[[4-(4-chlorophenyl)methyl]sulfonyl]-4-(1-piperazinyl)- (9CI)
 (CA INDEX NAME)




RN 412049-01-5 CAPLUS
 CN 1H-Indole, 1-[[4-(4-methylphenyl)methyl]sulfonyl]-4-(1-piperazinyl)- (9CI)
 (CA INDEX NAME)



RN 412049-02-6 CAPLUS
 CN 1H-Indole, 1-[[1,1-diphenylethyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
 INDEX NAME)




RN 412049-03-7 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)


RN 412049-04-8 CAPLUS

CN Benzamide, N-[[5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 412049-05-9 CAPLUS

CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-
(9CI) (CA INDEX NAME)




RN 412049-10-6 CAPLUS

CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 412049-11-7 CAPLUS


CN 1H-Indole, 5-[4-(1-methylethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI)
(CA INDEX NAME)




RN 412049-12-8 CAPLUS

CN 1H-Indole, 5-[4-(1-methylethyl)-1-piperazinyl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)






RN 412049-13-9 CAPLUS

CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(4-propyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 412049-14-0 CAPLUS

CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-5-(4-propyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 412049-15-1 CAPLUS

CN 1H-Indole, 5-(4-methyl-1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-16-2 CAPLUS
 CN 1H-Indole, 5-(4-methyl-1-piperazinyl)-1-(1-naphthalenylsulfonyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-17-3 CAPLUS
 CN 1H-Indole, 1-([1,1'-biphenyl]-4-ylsulfonyl)-5-(4-methyl-1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-18-4 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-19-5 CAPLUS
CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-20-8 CAPLUS
CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-21-9 CAPLUS
CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-22-0 CAPLUS
 CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-23-1 CAPLUS
 CN 1H-Indole,
 1-[(4-butoxyphenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-24-2 CAPLUS


CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-25-3 CAPLUS


CN 1H-Indole, 1-([1,1'-biphenyl]-4-ylsulfonyl)-5-[4-(phenylmethyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-26-4 CAPLUS

CN 1H-Indole,
1-(1-naphthalenylsulfonyl)-5-[4-(phenylmethyl)-1-piperazinyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-27-5 CAPLUS

CN 1H-Indole,

5-[4-(phenylmethyl)-1-piperazinyl]-1-[(4-propylphenyl)sulfonyl]-
, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-28-6 CAPLUS

CN 1H-Indole,


1-[(2-fluorophenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]-
, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-29-7 CAPLUS


CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-30-0 CAPLUS


CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-31-1 CAPLUS

CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-32-2 CAPLUS

CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(1-piperazinyl)-,


dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 412049-33-3 CAPLUS


CN 1H-Indole, 1-([1,1'-biphenyl]-4-ylsulfonyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 412049-34-4 CAPLUS

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 412049-35-5 CAPLUS

CN 1H-Indole, 5-(1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-,


dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 412049-36-6 CAPLUS


CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 412049-37-7 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 412049-40-2 CAPLUS


CN 1H-Indole, 2-iodo-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride

(9CI) (CA INDEX NAME)




● HCl

RN 412049-42-4 CAPLUS
CN 1H-Indole, 2-phenyl-1-(phenylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-45-7 CAPLUS
CN 1H-Indole, 2-methyl-1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)



RN 412049-49-1 CAPLUS


CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-50-4 CAPLUS


CN 1H-Indole, 4-(4-ethyl-1-piperazinyl)-1-[(2-methylphenyl)sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-51-5 CAPLUS


CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-54-8 CAPLUS

CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(3-methyl-1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-55-9 CAPLUS

CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 412049-56-0 CAPLUS

CN 1H-Indole, 4-[4-(1-methylethyl)-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-57-1 CAPLUS

CN 1H-Indole, 4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 412049-59-3 CAPLUS


CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 412049-60-6 CAPLUS
CN 1H-Indole, 4-(4-ethyl-1-piperazinyl)-1-(phenylsulfonyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-61-7 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-62-8 CAPLUS


CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-63-9 CAPLUS


CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 412049-64-0 CAPLUS
 CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




RN 412049-65-1 CAPLUS
 CN 1H-Indole, 1-[(4-phenoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-66-2 CAPLUS
CN 1H-Indole, 1-[[4-(4-chlorophenyl)methyl]sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-67-3 CAPLUS
CN 1H-Indole, 1-[[4-(4-methylphenyl)methyl]sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-68-4 CAPLUS

CN 1H-Indole, 1-[(1,1-diphenylethyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 412049-69-5 CAPLUS


CN 1H-Indole, 4-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-70-8 CAPLUS


CN Benzamide, N-[[5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thienyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-71-9 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-72-0 CAPLUS

CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)

(CA INDEX NAME)




RN 412049-73-1 CAPLUS
CN 1H-Indole, 1-[(4-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-74-2 CAPLUS
CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-75-3 CAPLUS
CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-76-4 CAPLUS
CN 1H-Indole, 1-[[(1E)-2-phenylethenyl]sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:89998 CAPLUS
DOCUMENT NUMBER: 136:129087
TITLE: New combination of serotonin 5-HT_{2c} agonist and 5-HT₆
antagonist as pharmaceutical formulation, and
therapeutic uses
INVENTOR(S): Jossan, Sukhwinder; Nilsson, Bjorn M.; Sakariassen,
Kjell S.; Svartengren, Jan
PATENT ASSIGNEE(S): Biovitrum AB, Swed.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008178	A1	20020131	WO 2001-SE1651	20010719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			SE 2000-2754	A 20000721

Habte

<05/15/2002

AB The invention relates to a method of preventing or treating a disease related to the 5-HT_{2c} receptor and the 5-HT₆ receptor, comprising administering to a human or animal subject in need thereof a 5-HT_{2c} receptor agonist and a 5-HT₆ receptor antagonist in sufficient amts. to provide a therapeutic affect. The invention also relates to a pharmaceutical compn. comprising an effective amt. of a combination of a 5-HT_{2c} receptor agonist and a 5-HT₆ receptor antagonist, and optionally a pharmaceutically acceptable carrier. The pharmaceutical combination of the invention may be used to treat eating disorders, CNS disorders, urinary incontinence, and glaucoma.


IT **393508-48-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction; serotonin 5-HT_{2c} agonist-5-HT₆ antagonist combination pharmaceutical, and therapeutic uses)

RN 393508-48-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT **393508-47-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP.(Preparation); USES (Uses)

(serotonin 5-HT_{2c} agonist-5-HT₆ antagonist combination pharmaceutical, and therapeutic uses)

RN 393508-47-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
9.17	149.66

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.24	-1.24

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:28:36 ON 15 MAY 2002